EUVIMEDDécouvrir EUVIMED
Open access · CC BY 4.0

Topical Application of Everolimus Attenuates Lens-Induced Myopia Through mTORC1 Suppression

Ruiheng Zhang, Chuyao Yu, Yitong Li, Jiaoyue Dong, Haotian Wu, Yuhang Yang, Xuhan Shi, Wenda Zhou, Hanqing Zhao, Bingyu Cai, Shanshan Wang, Li Dong and 4 more

Investigative Ophthalmology & Visual Science · 2025

DOI: 10.1167/iovs.66.12.55 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Ruiheng Zhang and 15 co-authors. Institution: Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University…. Major MEDLINE topics: Everolimus, Mechanistic Target of Rapamycin Complex 1, Myopia, Immunosuppressive Agents. Cited 3 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0).

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Purpose

The mechanistic target of rapamycin complex 1 (mTORC1) signaling has been reported to regulate lens-induced myopia (LIM) in guinea pigs. To address the challenge of delivering lipophilic mTORC1 inhibitors to the posterior eye segment, we developed a novel topical ophthalmic formulation of everolimus, a second-generation rapamycin derivative available only orally, and evaluated its antimyopic efficacy, ocular pharmacokinetics, and safety.

Methods

Vehicle formulations were optimized for delivering everolimus to the RPE-choroid complex. The efficacy of different concentrations of everolimus eye drops was tested in 3-week-old male pigmented guinea pigs that underwent LIM. We examined mTORC1 signaling activation, axial elongation, refractive changes, and fundus morphology. Pharmacokinetics was assessed in guinea pigs and New Zealand white rabbits. Ocular safety was evaluated through slit-lamp and fundus examinations, intraocular pressure measurements, and histologic analysis.

Results

The optimized formulation of everolimus eye drops (0.001%, 0.01%, and 0.1% w/v) significantly attenuated axial elongation by 0.10 ± 0.03 mm (P = 0.054), 0.11 ± 0.02 mm (P = 0.001), and 0.14 ± 0.03 mm (P = 0.001), respectively. The everolimus eye drops also attenuated fundus tessellation, choroidal thinning, and mTORC1 activation. Peak everolimus concentrations in the RPE-choroid complex of guinea pigs ranged from 5.6 to 103 ng/g, with a Tmax of 1 hour. In rabbits, 0.005% to 0.01% everolimus eye drops achieved concentrations in the RPE-choroid complex comparable to the therapeutic levels in guinea pigs. No corneal, lenticular, retinal toxicity, or intraocular pressure alterations were observed.

Conclusions

This novel ophthalmic formulation effectively delivered everolimus to the posterior segment and inhibited myopia progression, supporting its clinical potential for myopia control.

Subjects

MeSH terms (MEDLINE)

EverolimusMechanistic Target of Rapamycin Complex 1MyopiaImmunosuppressive AgentsLens, CrystallineAnimalsGuinea PigsRabbitsMaleDisease Models, AnimalOphthalmic SolutionsAdministration, TopicalRefraction, OcularIntraocular PressureRetinal Pigment Epithelium

Substances

EverolimusMechanistic Target of Rapamycin Complex 1Ophthalmic SolutionsImmunosuppressive Agents

Authors and institutions

  • Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Beijing Ophthalmology & Visual Sciences Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
  • Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.
  • University of Chinese Academy of Sciences, Beijing, China.

Cite

APA

Zhang, R., Yu, C., Li, Y., Dong, J., Wu, H., Yang, Y., Shi, X., Zhou, W., Zhao, H., Cai, B., Wang, S., Dong, L., Shao, L., Li, W., Jonas, J. B., & Wei, W. (2025). Topical Application of Everolimus Attenuates Lens-Induced Myopia Through mTORC1 Suppression. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.12.55

Vancouver

Zhang R, Yu C, Li Y, Dong J, Wu H, Yang Y, et al. Topical Application of Everolimus Attenuates Lens-Induced Myopia Through mTORC1 Suppression. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.12.55

BibTeX
@article{Zhang2025,
  author = {Zhang, Ruiheng and Yu, Chuyao and Li, Yitong and Dong, Jiaoyue and Wu, Haotian and Yang, Yuhang and Shi, Xuhan and Zhou, Wenda and Zhao, Hanqing and Cai, Bingyu and Wang, Shanshan and Dong, Li and Shao, Lei and Li, Wei and Jonas, Jost B and Wei, Wenbin},
  title = {Topical Application of Everolimus Attenuates Lens-Induced Myopia Through mTORC1 Suppression},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2025},
  doi = {10.1167/iovs.66.12.55}
}
Start for free →